Business Context and Reporting Period
This Form 8-K is filed by Capricor Therapeutics, Inc. on July 29, 2026. The report details significant developments regarding the Company's Phase 3 clinical trial (HOPE-3) for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD), and a recent FDA inspection.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory events rather than financial performance.
Material Changes and Clinical Updates
- HOPE-3 Trial Publication: Final one-year results from the Phase 3 HOPE-3 trial were published in The Lancet following independent peer review.
- Statistical Model Update: The Company updated its statistical model for the key secondary endpoint, Left Ventricular Ejection Fraction (LVEF):
- Revised Result: p=0.09 (1.8 percentage point treatment difference).
- Previously Reported: p=0.04 (2.4 percentage point treatment difference).
- Subgroup Analysis: In the pre-specified cardiomyopathy subgroup, the result remains nominally significant at p=0.02 (2.8 percentage point treatment difference).
- Primary Endpoint: The primary efficacy endpoint result and all other trial data remain unchanged.
Regulatory Events and Risks
- FDA BIMO Inspection: The FDA conducted a Bioresearch Monitoring (BIMO) inspection of clinical operations from July 6 to July 20, 2026.
- Form FDA 483: The FDA issued a Notice of Inspectional Observations citing one observation regarding standard operating procedures, documentation practices, vendor oversight, and audit report timeliness.
- Company Response: Capricor states the observation does not affect the integrity or reliability of the HOPE-3 data. A formal response is being prepared.
Investor Verification Checklist
- Verify the impact of the revised LVEF statistical model (p=0.09) on the FDA's assessment of the Biologics License Application.
- Review the Company's formal response to the Form FDA 483 to ensure no further regulatory actions are required.
- Confirm the status of the primary efficacy endpoint, which remains unchanged despite the secondary endpoint update.
- Monitor future communications regarding the FDA's final decision on the Deramiocel application.